Paeds Cases · haematology-oncology-and-transfusion
Tumour lysis syndrome and oncologic emergencies: Case
Clinical long case of a seven-year-old boy with a Burkitt lymphoma and a high tumour lysis risk, covering the risk assessment, the prophylaxis with the hyperhydration and the rasburicase before the first dose, the recognition and the management of the tumour lysis syndrome by the Cairo-Bishop definition, the airway-first principle for the anterior mediastinal mass, and the urgent imaging and steroid for the spinal cord compression.
On this page & tools
Target exams
Framing the case
This seven-year-old boy with the Burkitt lymphoma sits at the very top of the tumour lysis risk. The large abdominal mass, the lactate dehydrogenase of three thousand, and the elevated urate together mark a high tumour burden and a high cell turnover, and the start of the chemotherapy will release a torrent of the intracellular contents. The framework that organises the case is the recognition that the tumour lysis is predictable and preventable, and the first decision is to put the prophylaxis in place before the first dose of the chemotherapy. [3]
The risk assessment and the prophylaxis
The boy is high risk by the Cairo stratification, because the Burkitt lymphoma has the very highest cell turnover of any childhood tumour, with a doubling time of around twenty-four hours. The prophylaxis is the foundation of the management, and it begins before the first dose. The hyperhydration with an isotonic fluid that contains no potassium is run at two to three litres per square metre per day to maintain a urine output above two millilitres per kilogram per hour. The fluid is potassium-free because the child is at risk of the hyperkalaemia. [1]
The rasburicase, a recombinant urate oxidase that converts the existing uric acid into the soluble allantoin, is given at zero point one five to zero point two milligrams per kilogram, and the glucose-six-phosphate-dehydrogenase status is checked first, because the rasburicase is contraindicated in the deficiency and causes a severe haemolysis and a methaemoglobinaemia. The biochemistry of the potassium, the phosphate, the calcium, the creatinine, and the urate is monitored every four to six hours for the first twenty-four to forty-eight hours, and the renal replacement therapy is kept on standby. [1][9]
The recognition and the management if it declares
Should the tumour lysis declare, the recognition rests on the Cairo-Bishop definition. The laboratory tumour lysis syndrome is two or more of the urate over four hundred and seventy-six micromoles per litre, the potassium over six millimoles per litre, the phosphate over two point one millimoles per litre in the child, and the corrected calcium under one point seven five millimoles per litre, within three days before to seven days after the cytotoxic therapy, each or a twenty-five percent change from the baseline. The clinical form adds the acute kidney injury, the cardiac arrhythmia or sudden death, or the seizure. [2]
The management of the declared syndrome is staged. The hyperkalaemia is the immediate killer, and the calcium gluconate is given the moment the ECG shows the peaked T waves and the widened QRS, to stabilise the cardiac membrane within minutes, followed by the insulin with the glucose and the salbutamol to shift the potassium into the cell. The asymptomatic hypocalcaemia is not corrected in the high-phosphate state, because the correction drives the calcium-phosphate deposition and worsens the kidney injury. The refractory hyperkalaemia, the oliguria, and the volume overload are the indications for the renal replacement therapy. [5]
The structural emergencies
Should the boy instead present with a progressive leg weakness and a bowel or bladder change, the malignant spinal cord compression would be assumed until the magnetic resonance imaging proved otherwise. The intravenous dexamethasone would be started early to reduce the cord oedema, the urgent whole-spine magnetic resonance imaging would define the level and the cause, and the definitive management would be the emergency decompression, the radiotherapy, or the chemotherapy. The ambulation at the presentation is the strongest predictor of the ambulation at the outcome, and the window to preserve the walking is twenty-four to forty-eight hours. [7]
Should the boy develop a fever with a neutrophil count under zero point five times ten to the nine per litre, the febrile neutropenia would be managed empirically with an antipseudomonal beta-lactam such as the cefepime or the piperacillin-tazobactam within one hour after the blood cultures, because the fever in the neutropenic child is a bacterial emergency. [5]
Communication and the family
The family is counselled honestly on the high tumour lysis risk, on the rationale for the hyperhydration and the rasburicase, and on the need for the close biochemical monitoring in the first days of the therapy. The glucose-six-phosphate-dehydrogenase check is explained, and the family is taught the warning signs of the fever and the new symptom and the need to return at once. The boy is prepared in an age-appropriate way, and the multidisciplinary team is assembled around the family. [4]
References
- [1]Howard SC, Avagyan A, Workeneh B, Pui CH Tumour lysis syndrome Nat Rev Dis Primers, 2024.PMID 39174582
- [2]Cairo MS, Bishop M Tumour lysis syndrome: new therapeutic strategies and classification Br J Haematol, 2004.PMID 15384972
- [3]Cairo MS, Coiffier B, Reiter A, Pui CH Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases Br J Haematol, 2010.PMID 20331465
- [4]Perissinotti AJ, Bishop MR, Bubalo J Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panel Cancer Treat Rev, 2023.PMID 37579533
- [5]Prusakowski MK, Cannone D Pediatric Oncologic Emergencies Hematol Oncol Clin North Am, 2017.PMID 29078932
- [7]Quraishi NA, Palliyil N, Hassanin MA Malignant spinal cord compression in the paediatric population-a systematic review, meta-analysis. Eur Spine J, 2023.PMID 37338630
- [9]Hammami MB, Qasim A, Thakur R, Soubra R, Al-Shash S Rasburicase-induced hemolytic anemia and methemoglobinemia: a systematic review of current reports Ann Hematol, 2024.PMID 37468669